editors have chosen someone with my well-known views on the 6-minute walk (6MW) to write an editorial on the subject? Well, remember that data should always trump bias, and I can hopefully assess the existent data and the manuscript by Gabler et al 1 (although it does, at least in part, uphold my views) in an unbiased fashion. For the purpose of this discussion, I will examine several points related to the use of the 6MW in patients with pulmonary arterial hypertension (PAH) and in the clinical trials examining the effect of treatment in this disease entity.
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1. Baseline 6MW and prognosis in patients with PAH. 2. Change in 6MW with treatment and prognosis in patients with PAH. 3. Absolute value of the 6MW and prognosis in patients with PAH. 4. Clinically (not statistically) significant improvement in 6MW with treatment in patients with PAH. 5. Value of the 6MW alone as a prognostic indicator in patients with PAH.
Although the 6MW is considered a potential surrogate for survival in patients with PAH, it has never been thoroughly tested for its predictive value. Moreover, it is often used for critical decisions about the efficacy of currently available therapies, despite the fact that none of the clinical trials using it as an end point were really designed to test this premise. In this issue of Circulation, Gabler et al 1 have examined the correlation between change in 6MW during 12 weeks of treatment from the 10 randomized, placebo-controlled trials (RCT) submitted to the US Food and Drug Administration and the probability of a clinical event. In addition, the authors attempted to determine a threshold effect for the change in 6MW that would indicate a significant reduction in such clinical events. After examining the change in 6MW in the Ͼ2400 patients from these trials, the authors concluded that, although active treatment did decrease the probability of a clinical event, the change in 6MW did not explain a large proportion of the treatment effect. As such, it may have only modest validity as a surrogate end point for clinical trials and, thus, may not be a sufficient surrogate. In addition, the authors found the clinical threshold value to be 41.8 meterswell above the statistically significant value of change in 6MW that has been achieved in many trials of currently approved treatment regimens.
So, what does all this mean? These results are in line with what many of us inherently believe from years of experience with patients suffering from this disease, and are, in some ways, contradictory to the pre-existent literature. However, this study does have the advantage of an extremely large database and excellent statistical methods.
Let's look at the 6MW a little more realistically. In general, it has been used extensively because it is easy to perform, requires little expertise or facilities, is inexpensive, and is relatively reproducible. In addition to the distance walked during the test, the degree of dyspnea (Borg scale) and the oxygen saturation can also be determined. Moreover, the change in 6MW has been the primary end point in most pivotal RCT in PAH and has been, until the present, the most accepted end point for evaluating treatment effect in PAH by the U.S. Food and Drug Administration and the European Agency for Evaluation of Medicinal Products.
On the other hand, the 6MW has not been validated in subgroups of PAH patients and is clearly influenced by sex, age, height, body weight, patient motivation, and, often, the underlying disease state (ie, scleroderma), although it is rarely, if ever, corrected for any of these factors. In addition, the change in 6MW necessary for the PAH patient to notice an improvement in clinical status or predict a reduction in clinical events has never been conclusively established.
Baseline 6MW and Prognosis in Patients With PAH
Although early studies suggested that the 6MW could predict outcome, 2 a recent meta-analysis questioned this association. 3 However, more recent data do strongly suggest that the baseline 6MW is predictive of outcome in PAH. 4 -6 Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) and the French Registry demonstrate that the baseline 6MW is predictive of outcome. 4, 5 In the REVEAL Registry, 4 a baseline 6MW Ն440m was associated with longer survival, whereas a 6MW of Ͻ165 m was associated with increased mortality at 1 year. In the French Registry, 5 a greater 6MW was significantly and positively associated with survival. In
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From the Pulmonary Hypertension Center, Boston University School addition, multivariable analysis indicated that a greater 6MW, among other factors, was significantly associated with improved survival and was a strong predictor of death in PAH.
In addition, in a recent study of follow-up assessments in patients with PAH, the baseline 6MW was an independent predictor of survival. 6 Thus, despite the obvious limitations of the 6MW, the prognostic implications of this evaluation at baseline seem incontrovertible.
Change in 6MW With Treatment and Prognosis in Patients With PAH
The correlation between the change in 6WM with treatment and prognosis in PAH, although seemingly obvious, has not been conclusively established. In fact, a recent meta-analysis demonstrated that, although current treatment strategies for PAH significantly reduce all-cause mortality by 39%, the improved survival had no relationship to the change in 6MW. 7 The study by Gabler et al 1 confirms this finding, demonstrating that the average difference in the change in 6MW was 22.4 meters with active treatment. Despite a decreased probability of a clinical event with treatment, the 6MW only accounted for a small proportion of this effect (22.1%). Although the precise threshold for a valid surrogate is controversial, 8, 9 most experts in the field would agree that this proportion is well below any widely-accepted validation level. Thus, in sum, currently available data demonstrate that treatment of PAH have not improved 6MW to a level that is neither clinically apparent to the patient nor sufficient to mitigate a clinical event.
Absolute Value of the 6MW and Prognosis in Patients With PAH
Is there an absolute value of 6MW that is associated with improved survival in PAH and, if so, what is it? Sitbon et al 10 demonstrated that patients who reached a 6WM of Ͼ380 meters 3 months after initiation of epoprostenol had a significantly better long-term survival than patients who did not reach this threshold. Based on this study, this value has been adopted in studies examining goal-directed therapy. 11 However, this value has not been validated for any oral agent, has never been proven in a robust RCT in any drug class, and may be too low in the current era of PAH treatment because of use of combination therapy and the REVEAL finding that the baseline 6MW associated with improved outcome is Ͼ440 meters. Thus, although there are currently several ongoing clinical trials using a fixed distance in 6WM as a guide for therapy, in sum, at the moment, we do not know the appropriate absolute target for the 6WM.
Clinically (Not Statistically) Significant Improvement in 6MW With Treatment in Patients With PAH
What is a clinically significant improvement in 6WM with treatment? This has been a difficult value to ascertain. Although most therapies for PAH have been approved based on statistical improvement in 6MW, it has never been clear that these improvements, especially the lower values, are noticeable to the patient. In their study, Gabler et al 1 suggest that necessary threshold for improvement in 6MW with treatment such that the probability of a clinical event is decreased is 41.8 meters. Interestingly, the authors found that only 4/21 drug combinations would meet this standard. Even if this threshold were reduced to as low as 25.7 meters, the minority of approved drug combinations would meet this standard. Thus, in sum, it appears that most of the therapies that have been approved for treatment of PAH have not improved 6MW to a level that is clinically neither apparent to the patient nor sufficient to mitigate a clinical event. , have moved to event-driven protocols, combining many indicators of clinical status to give a more accurate picture of the effect of treatment on patient response and outcome. The study by Gabler et al, 1 the available data, and the experience of individuals in the field all suggest that the 6MW alone has limited use in our care of patient with PAH. New trial designs with more expansive end points, as noted above, might better address clinical benefits and, hopefully, provide more reliable and valid surrogate markers for use in this disease.
Value of the 6MW Alone as a Prognostic Indicator in Patients With PAH

